Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fouts

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Structure (London, England : 1993)|April 5, 2016
Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 RegionWilliam D Tolbert, Neelakshi Gohain, Maxime Veillette, et al.
NPJ Vaccines|February 9, 2021
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virusThomas W Geisbert, Kathryn Bobb, Viktoriya Borisevich, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Recombinant human secretory phospholipase A2 released thromboxane from guinea pig bronchoalveolar lavage cells: in vitro and ex vivo evaluation of a novel secretory phospholipase A2 inhibitorJ H Fleisch, C T Armstrong, C R Roman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2012
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingYongjun Guan, Marzena Pazgier, Mohammad M Sajadi, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Cell Reports|April 7, 2015
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.
Molecular Systems Biology|May 4, 2019
Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protectionSrivamshi Pittala, Kenneth Bagley, Jennifer A Schwartz, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2015
Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infectionTimothy R Fouts, Kenneth Bagley, Ilia J Prado, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Structure (London, England : 1993)|April 5, 2016
Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 RegionWilliam D Tolbert, Neelakshi Gohain, Maxime Veillette, et al.
NPJ Vaccines|February 9, 2021
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virusThomas W Geisbert, Kathryn Bobb, Viktoriya Borisevich, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Recombinant human secretory phospholipase A2 released thromboxane from guinea pig bronchoalveolar lavage cells: in vitro and ex vivo evaluation of a novel secretory phospholipase A2 inhibitorJ H Fleisch, C T Armstrong, C R Roman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2012
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingYongjun Guan, Marzena Pazgier, Mohammad M Sajadi, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Cell Reports|April 7, 2015
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.
Molecular Systems Biology|May 4, 2019
Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protectionSrivamshi Pittala, Kenneth Bagley, Jennifer A Schwartz, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2015
Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infectionTimothy R Fouts, Kenneth Bagley, Ilia J Prado, et al.
Pageof 15